2 active not recruiting, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
Follow Restorbio Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults RTB101, Placebo - Covid19 | Phase 2 | Active not recruiting | Restorbio Inc. | 60 | 2020-10-13 | 2021-02-09 |
| Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes RTB101, Placebo - COVID19 | Phase 2 | Terminated | Restorbio Inc. | 36 | 2020-07-11 | 2021-02-10 |
| Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly Placebo, BEZ235, BEZ235 plus everolimus (RAD001) - Respiratory Tract Infections | Phase 2 | Active not recruiting | Restorbio Inc. | 652 | 2017-11-15 | 2018-05-16 |
COVID-19 (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Virus Diseases (2) · Respiratory Tract Infections (1)
dactolisib (3) · Everolimus (1)
United States (3)
R01AG064802 (1)